SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) — Crinetics Prescribed drugs, Inc. (Nasdaq: NASDAQ:) at this time introduced that it’s going to report second quarter 2024 monetary outcomes on Thursday, August 8, 2024 after the market closes. Firm administration will host a convention name at 4:30 p.m. ET that day to debate monetary outcomes and supply a enterprise replace.
Convention Name & Webcast
Thursday, August 8th @ 4:30 PM ET
Home: | 1-800-267-6316 |
Worldwide: | 1-203-518-9783 |
Convention ID: | CRNXQ2 |
Individuals can use the dial-in numbers above OR entry the decision through reside webcast on the Occasions part of the Crinetics web site. To make sure a well timed connection, it’s endorsed that contributors dial-in or register no less than quarter-hour previous to scheduled begin of the decision.
The webcast will probably be archived on the Investor Relations sections of www.crinetics.com.
About Crinetics Prescribed drugs
Crinetics Prescribed drugs is a scientific stage pharmaceutical firm centered on the invention, improvement, and commercialization of novel therapeutics for endocrine illnesses and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor sort 2 (SST2) agonist, is in Section 3 scientific improvement for acromegaly and Section 2 scientific improvement for carcinoid syndrome related to neuroendocrine tumors. Crinetics can be growing atumelnant (CRN04894), an investigational, first-in-class, oral ACTH antagonist, that’s at present finishing Section 2 scientific research for the remedy of congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. The entire Firm’s drug candidates are orally delivered, small molecule new chemical entities ensuing from in-house drug discovery efforts, together with extra discovery packages addressing quite a lot of endocrine circumstances reminiscent of hyperparathyroidism, polycystic kidney illness, Graves’ illness, thyroid eye illness, diabetes and weight problems.
Contact:
Gayathri Diwakar
Head of Investor Relations
[email protected]
(858) 345-6340
Media:
Natalie Badillo
Head of Company Communications
[email protected]
(858) 345-6075
Supply: Crinetics Prescribed drugs, Inc.